Stents, Bioresorbable

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE...

bioresorbable stents, dissolving stents

A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC) meetings is that bioresorbable stents will eventually replace conventional metallic stents...

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's Absorb bioresorbable vascular scaffold (BVS) in the United States, Japan and China. Combined, the U.S., Japan and China ac...

Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended...

A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-eluting stents (BP-SES) to durable polymer sirolimus-eluting...
September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting...
ABSORB II Study DES Xience Abbot Vascular
Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and...
bioresorbable stents, dissolving stents, Absorb stent, BVS
A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC)...
Micell Technologies Inc.'s thin-strut stent features elimination of the coating from the stent in 45-60 days and the complete absorption of

Articles

ABSORB II Study DES Xience Abbot Vascular
Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and...
bioresorbable stents, dissolving stents, Absorb stent, BVS
A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC)...
Elixir Medical Corp. DESolve 100 CE mark
Elixir Medical Corp. received CE mark approval for its DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.
April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's Absorb bioresorbable vascular...

Video Center

By Dave Fornell, editor of DAIC Magazine The key take away messages from the 26th annual...
5 days 2 hours ago
As technology continues to advance for all diagnostic imaging modalities, it sometimes reminds me...
3 weeks 6 days ago
The Society of Cardiovascular Computed Tomography (SCCT) annual meeting July 10-13 in San Diego...
9 weeks 5 days ago
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...
The webinar "PET/CT: A New Frontier" discusses potential benefits of digital relative to analog PET/CT. The session will discuss how digital PET can improve...
Centricity Cardio Enterprise, Cardiac PACS, Cardio PACS, CVIS
This webinar demonstrates the Centricity Cardio Enterprise Solution (CCE), a solution that can help cardiology departments and hospital administrators to...

Comparison Charts

Sorry there is no data available